ClinicalTrials.govpublic full text
A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab
multiple sclerosis, multiple sclerosis, relapsing-remitting, natalizumab, drug holiday, alternative dosing, extended dosing, interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 898484
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.